Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
    21.
    发明授权
    Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 有权
    使用FGF-5增强视网膜神经元存活和治疗眼部疾病的方法

    公开(公告)号:US06331523B1

    公开(公告)日:2001-12-18

    申请号:US09240952

    申请日:1999-01-29

    IPC分类号: A61K3816

    摘要: The present invention relates to the use of FGF-5 polypeptides to delay, prevent or rescue retinal neurons, including photoreceptors, other retinal cells or supportive cells (e.g. Müller cells or RPE cells) from injury and degradation. Conditions comprehended by treatment of the present FGF-5 polypeptides (including variants), antibodies, compositions and articles of manufacture include: retinal detachment, age-related and other maculopathies, photic retinopathies, surgery-induced retinopathies (either mechanically or light-induced), toxic retinopathies including those resulting from foreign bodies in the eye, diabetic retinopathies, retinopathy of prematurity, viral retinopathies such as CMV or HIV retinopathy related to AIDS, uveitis, ischemic retinopathies due to venous or arterial occlusion or other vascular disorder, retinopathies due to trauma or penetrating lesions of the eye, peripheral vitreoretinopathy, and inherited retinal degenerations. Exemplary retinal degenerations include e.g., hereditary spastic paraplegia with retinal degeneration (Kjellin and Barnard-Scholz syndromes), retinitis pigmentosa, Stargardt disease, Usher syndrome (refinitis pigmentosa with congenital hearing loss), and Refsum syndrome (retinitis pigmentosa, hereditary hearing loss, and polyneuropathy). Additional disorders which result in death of retinal neurons include, retinal tears, detachment of the retina and pigment epithelium, degenerative myopia, acute retinal necrosis syndrome (ARN), traumatic chorioretinopathies or contusion (Purtscher's Retinopathy) and edema.

    摘要翻译: 本发明涉及FGF-5多肽延迟,预防或挽救视网膜神经元(包括光感受器,其他视网膜细胞或支持性细胞(例如Müller细胞或RPE细胞))免受损伤和降解的用途。 通过治疗本发明的FGF-5多肽(包括变体),抗体,组合物和制品所理解的病症包括:视网膜脱离,年龄相关性和其他黄斑病变,光学视网膜病变,手术诱导的视网膜病变(机械或光诱导) ,包括由眼睛异物引起的有毒视网膜病变,糖尿病性视网膜病变,早产儿视网膜病变,病毒性视网膜病变如CMV或艾滋病相关的HIV视网膜病变,葡萄膜炎,由静脉或动脉闭塞或其他血管疾病引起的缺血性视网膜病变,视网膜病变 眼睛的创伤或穿透损伤,外周玻璃体视网膜病变和遗传性视网膜变性。 示例性视网膜变性包括例如具有视网膜变性的遗传性痉挛性截瘫(Kjellin和Barnard-Scholz综合征),色素性视网膜炎,Stargardt病,Usher综合征(具有先天性听力损失的色素性纤维素炎)和Refsum综合征(色素性视网膜炎,遗传性听力损失和 多发性神经病)。 导致视网膜神经元死亡的其他病症包括视网膜撕裂,视网膜和色素上皮剥离,退行性近视,急性视网膜坏死综合征(ARN),创伤性脉络膜视网膜病变或挫伤(Purtscher's Retinopathy)和水肿。